Full-length merozoite surface protein 1 formulated with GLA-SE adjuvant in malaria pre-exposed adults: a randomised, controlled, double-blind, parallel-group, single-centre Phase Ib trial
Sumaya Biotech GmbH & Co. KG, Heidelberg, funded this study partly through support by a Venture Loan Agreement to Sumaya Biotech GmbH & Co. KG by the EU Malaria Fund Berlin GmbH & Co. KG.
Authors
- Ernst Böhnlein
- Richard Thomson-Luque (ORCID: https://orcid.org/0000-0001-8378-9497)
- Ally Olotu (ORCID: https://orcid.org/0000-0001-6696-1937)
- Omary Hassan
- Kristin Fürle (ORCID: https://orcid.org/0000-0001-6835-3759)
- Sarah Mswata
- Andrea Aschenbrenner
- Maxmillian Mpina (ORCID: https://orcid.org/0000-0002-9300-6430)
- Michael Lanzer (ORCID: https://orcid.org/0000-0002-0220-6526)
- Mohanji Saxena (ORCID: https://orcid.org/0009-0002-4064-0638)
- Fiona Vanobberghen (ORCID: https://orcid.org/0000-0002-8908-0953)
- Claudia Daubenberger (ORCID: https://orcid.org/0000-0001-7136-0642)
- Ibrahim Sasamalo
- Viktoria Kiehl
- Daniel H. Paris (ORCID: https://orcid.org/0000-0003-4743-5987)
- Aina-ekisha Kahatano
- Nsiande Urasa
- Suzanne Gajewski
Institutions
- Ifakara Health Institute (TZ)
- Swiss Tropical and Public Health Institute (CH)
- University of Basel (CH)
- Heidelberg University (DE)
- University Hospital Heidelberg (DE)
Publication Details
- Journal
- EClinicalMedicine
- Published
- 2025-10-25
- DOI
- https://doi.org/10.1016/j.eclinm.2025.103585
- Citations
- 1
- Primary Topic
- Malaria Research and Control
- Type
- article
- Field-Weighted Citation Impact
- 1.88